related research:
Chinese drug loberamisal extends stroke treatment window from 6 hours to 2 days
"The large-scale multicentre phase 3 trial found that 70 per cent of patients who received loberamisal intravenously within two days of a stroke regained complete functional independence – an increase of 13 percentage points over standard care alone."